恒瑞医药(600276.SH)：SHR-7782注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-7782 injection, a novel biopharmaceutical aimed at treating advanced solid tumors [1] Company Summary - SHR-7782 injection is a self-developed therapeutic biopharmaceutical that specifically binds to tumor cell surface antigens to kill tumor cells [1] - The clinical trial is set to commence shortly, indicating progress in the company's research and development efforts [1] - The total R&D investment for the SHR-7782 injection project has reached approximately 48.2 million yuan [1] Industry Summary - Currently, there are no similar drugs approved for market use domestically or internationally, highlighting a potential competitive advantage for the company [1]